跳转至内容
Merck
CN
所有图片(1)

主要文件

528884

Sigma-Aldrich

Polo-like Kinase Inhibitor V, Poloxin

The Polo-like Kinase Inhibitor V, Poloxin, also referenced under CAS 321688-88-4, controls the biological activity of Polo-like Kinase. This small molecule/inhibitor is primarily used for Phosphorylation & Dephosphorylation applications.

别名:

Polo-like Kinase Inhibitor V, Poloxin, Polo-like Kinase Inhibitor V, 2-isopropyl-5-methyl-4-(2-methylbenzoyloxyimino)cyclohexa-2,5-dienone

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C18H19NO3
分子量:
297.35
MDL编号:
UNSPSC代码:
12352200

质量水平

方案

≥99% (HPLC)

表单

solid

制造商/商品名称

Calbiochem®

储存条件

OK to freeze
protect from light

颜色

yellow

溶解性

DMSO: 25 mg/mL, clear, yellow

运输

ambient

储存温度

2-8°C

InChI

1S/C18H19NO3/c1-11(2)15-10-16(13(4)9-17(15)20)19-22-18(21)14-8-6-5-7-12(14)3/h5-11H,1-4H3/b19-16-

InChI key

CMOJHDQJJPIVEC-MNDPQUGUSA-N

一般描述

A thymoquinone derivative, non-ATP competitive Polo-like Kinase 1 (Plk1) inhibitor specifically targeting the polo-box domain (PBD) of Plk1 (IC50) = 4.8 µM. Reduces both chromosome and kinetochoral localization of Plk1, induces chromosome congression defects , mitotic arrest in prometaphase, and apoptosis in HeLa cells at 25 µM. Exhibits anti-proliferative effects in a range of cancer cell lines, and in a mouse Xenograft model involving HeLa and MDA-MB-231 cells at 40 mg/kg.

包装

Packaged under inert gas

警告

Toxicity: Standard Handling (A)

重悬

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.

其他说明

Reindl, W., et al. 2008. Chem Biol.15, 459.
Yuan, J., et al. 2011, Am J Pathol179, 2091.

法律信息

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

储存分类代码

11 - Combustible Solids

WGK

WGK 3


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Sol-Bi Shin et al.
Journal of cellular physiology, 230(12), 3057-3067 (2015-05-16)
The expression of polo-like kinase 1 (Plk1) correlates with malignancy and is thus recognized as a target for cancer therapy. In addition to the development of ATP-competitive Plk1 inhibitors, the polo-box domain (PBD), a unique functional domain of PLKs, is

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门